ProPhase Labs, Inc. Proceeds from Warrant Exercises
ProPhase Labs, Inc. (PRPH) reported Proceeds from Warrant Exercises of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-01.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromWarrantExercises · last filed 2025-04-01
- ProPhase Labs, Inc. proceeds from warrant exercises for the quarter ending 2024-12-31 was $0.00.
- ProPhase Labs, Inc. proceeds from warrant exercises for the quarter ending 2023-12-31 was $0.00.
- ProPhase Labs, Inc. proceeds from warrant exercises for the quarter ending 2022-12-31 was $0.00.
- ProPhase Labs, Inc. proceeds from warrant exercises for the quarter ending 2018-12-31 was $0.00.
- ProPhase Labs, Inc. proceeds from warrant exercises for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ProPhase Labs, Inc. proceeds from warrant exercises for fiscal 2023 was $1.20M.
- ProPhase Labs, Inc. proceeds from warrant exercises for fiscal 2022 was $0.00.
- ProPhase Labs, Inc. proceeds from warrant exercises for fiscal 2018 was $338.00K, a 389.86% increase from fiscal 2017.
| Period end | Proceeds from Warrant Exercises 2 month | Proceeds from Warrant Exercises 3 month | Proceeds from Warrant Exercises 6 month | Proceeds from Warrant Exercises 9 month | Proceeds from Warrant Exercises 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $0.00 10-K · filed 2025-04-01 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $1.20M 10-K · filed 2025-04-01 | |||
| 2023-09-30 | $1.20M 10-K · filed 2025-04-01 | $1.20M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $0.00 derived: sum of 2 quarters · filed 2020-03-26 | $338.00K derived: sum of 3 quarters · filed 2020-03-26 | $338.00K 10-K · filed 2020-03-26 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $338.00K derived: sum of 2 quarters · filed 2019-11-12 | $338.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $338.00K 10-Q · filed 2019-08-12 | $338.00K 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$102.00K derived: sum of 2 quarters · filed 2019-03-26 | $0.00 derived: sum of 3 quarters · filed 2019-03-26 | $69.00K 10-K · filed 2019-03-26 | |
| 2017-09-30 | -$102.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $69.00K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $102.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-08-20 | $171.00K 10-Q/A · filed 2018-08-20 | |||
| 2017-03-31 | $69.00K 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |